Cargando…

Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies

Metastatic renal cell carcinoma (mRCC) treatments have rapidly evolved in the last few years. While vascular endothelial growth factor (VEGF) inhibition had previously been the mainstay of treatment for first-line advanced RCC therapy in the past decade, it has now rapidly changed into combination c...

Descripción completa

Detalles Bibliográficos
Autor principal: Aragon-Ching, Jeanny B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045961/
https://www.ncbi.nlm.nih.gov/pubmed/33884285
http://dx.doi.org/10.18632/oncoscience.528
_version_ 1783678759637876736
author Aragon-Ching, Jeanny B.
author_facet Aragon-Ching, Jeanny B.
author_sort Aragon-Ching, Jeanny B.
collection PubMed
description Metastatic renal cell carcinoma (mRCC) treatments have rapidly evolved in the last few years. While vascular endothelial growth factor (VEGF) inhibition had previously been the mainstay of treatment for first-line advanced RCC therapy in the past decade, it has now rapidly changed into combination checkpoint inhibitors with or without VEGF TKIs, although there remains a role for VEGF tyrosine kinase inhibitor monotherapy for patients with favorable-risk disease and for those with intermediate and poor-risk disease with the use of cabozantinib. Perspectives on the Quality-adjusted survival Time without Symptoms of disease or Toxicity (Q-TWiST) analysis for the CABOSUN trial, as well as different aspects of efficacy regarding different first-line therapy for advanced or metastatic RCC are discussed herein.
format Online
Article
Text
id pubmed-8045961
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-80459612021-04-20 Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies Aragon-Ching, Jeanny B. Oncoscience Research Perspective Metastatic renal cell carcinoma (mRCC) treatments have rapidly evolved in the last few years. While vascular endothelial growth factor (VEGF) inhibition had previously been the mainstay of treatment for first-line advanced RCC therapy in the past decade, it has now rapidly changed into combination checkpoint inhibitors with or without VEGF TKIs, although there remains a role for VEGF tyrosine kinase inhibitor monotherapy for patients with favorable-risk disease and for those with intermediate and poor-risk disease with the use of cabozantinib. Perspectives on the Quality-adjusted survival Time without Symptoms of disease or Toxicity (Q-TWiST) analysis for the CABOSUN trial, as well as different aspects of efficacy regarding different first-line therapy for advanced or metastatic RCC are discussed herein. Impact Journals LLC 2021-03-21 /pmc/articles/PMC8045961/ /pubmed/33884285 http://dx.doi.org/10.18632/oncoscience.528 Text en Copyright: © 2021 Aragon-Ching. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Perspective
Aragon-Ching, Jeanny B.
Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
title Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
title_full Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
title_fullStr Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
title_full_unstemmed Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
title_short Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
title_sort balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (rcc) studies
topic Research Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045961/
https://www.ncbi.nlm.nih.gov/pubmed/33884285
http://dx.doi.org/10.18632/oncoscience.528
work_keys_str_mv AT aragonchingjeannyb balancingefficacyandqualityoflifemeasurementsamongmetastaticrenalcellcarcinomarccstudies